Artelo Biosciences (ARTL) said Monday its first-in-human study of its non-opioid analgesic ART26.12 affirmed the "promising" safety and pharmacokinetic profile observed in preclinical trials.
Shares more than doubled as intraday trading volume catapulted to over 24.5 million from a daily average of about 73,000.
HC Wainwright upgraded Vor Biopharma (VOR) to a buy rating from neutral, with a price target of $3.
Shares surged 52%, with trading volume of over 52.9 million against a daily average of about 12.6 million.
Klotho Neurosciences (KLTO) said it is progressing with manufacturing and process development work for trials of KLTO-202, its gene therapy candidate for amyotrophic lateral sclerosis.
Shares advanced 61% as intraday trading volume soared to over 124.1 million from a daily average of about 39.2 million.
Price: 14.08, Change: +7.30, Percent Change: +107.67
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。